INVO (INVO Bioscience, Inc.) Net Profit

Corporate emblem and logo of INVO Bioscience, Inc. (INVO)

Slow growth in demand for oocyte maturation systems is limiting business efficiency, coinciding with a transition to AI-driven lending services and a name change to Janover. The net operating profit of INVO Bioscience, Inc. (INVO) on this chart reflects revenue dynamics, where the current value is -0.01. Management aims to scale its own clinic network by implementing affordable infertility treatments through unique cultivation technologies.

INVO: INVO Bioscience, Inc. Net Profit 07/04/2022 - 04/28/2025

Financial and market metric breakdowns for invobioscience.com (INVO)

- current quotes and average value forecast:
Market Chart INVO Bioscience|INVO - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization INVO Bioscience, Inc.|INVO - Total Company Value
- book capitalization data:
Net Assets per Single Share INVO Bioscience|INVO - Book Capitalization|Market Capitalization to Book Value invobioscience.com|INVO - Cumulative Company Assets
- debt and liquidity details:
Aggregate Debt to Equity INVO Bioscience, Inc.|INVO - Long-Term Debt to Capital|Current Liabilities to Capital INVO Bioscience|INVO - Company Aggregate Debts|Debt to Book Value Ratio INVO Bioscience, Inc.|INVO - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings INVO Bioscience|Quick Liquidity Indicator invobioscience.com
- earnings and valuation multiples information:
INVO - Net Profit
Fundamental valuation:INVO Bio
Product sample of INVO Bioscience, Inc.

Investors utilize this metric as a leading indicator of operational efficiency, assessing the business's ability to generate daily net cash flow. By analyzing the current profit level of INVO Bioscience, Inc. (INVO), calculated as the difference between total revenues and all expenses, one can confirm the commercial sustainability of INVO Bioscience, Inc. (INVO) through the implementation of innovative IVF systems in specialized clinics.

Key competitors

BSX - Net Financial Result|EW (Edwards Lifesciences) - Net Profit|Net Profit resmed.com|Company Net Income Insulet (PODD)|Company Net Income ZBH (Zimmer Biomet Holdings)|Net Profit COO (CooperVision)|Net Financial Result Align Corp (ALGN)|GMED: Net Income|Profit After Tax TMDX|ATEC: Net Profit|Company Net Income CryoLife (AORT)|ENOV (DJO Global) - Net Profit|Company Profit IART (Integra LifeSciences Inc.)|Net Income ESTA (Establishment Labs)|BBNX (betabionics.com) - Final Profit|Company Net Income IRADIMED IRMD|EMBC - Net Income|Tandem Diabetes - Net Profit|Company Net Income Axogen Surgical|SIBN: Net Profit|Company Profit OFIX|BVS (Bioventus) - Net Profit|OrthoPediatrics Inc. (KIDS) - Net Financial Result|Net Profit TMCI|Net Income Strata Medical SRTA|Net Profit CARL (Carlsmed Inc)|Net Profit rxsight.com RXST|CLPT - Company Net Income|STXS: Company Net Income|STIM (NeuroStar) - Net Income|Sight Sciences Inc - Final Profit|OBIO (Orchestra BioMed) - Net Profit|Company Net Income Anika ANIK|Company Net Income InspireMD (NSPR)|zhjmedical.com (ZJYL) - Annual Net Income|Vivani Medical - Net Income|Net Profit Xtant Medical Holdings, Inc. XTNT|NeuroOne Medical Technologies - Net Profit|Net Financial Result Modular Medical MODD|Myomo (MYO) - Company Net Income|Profit After Tax COCH (Envoy Medical Inc.)|Company Net Income Vivos Therapeutics, Inc|Net Income enVVeno Corp (NVNO)|Net Profit SINT|TNON - Company Net Income|Company Net Income Lifeward LFWD|AMIX: Company Profit|IVF: Net Income|Bone Biologics Inc - Profit After Payment of Taxes|AXNX: Net Profit|BIOL - Net Financial Result|Company Net Income Dynatronics Corp|Company Profit FNA (Paragon 28 Corp)